John D. Crispino - Publications

Affiliations: 
University of Chicago, Chicago, IL 
Area:
Molecular Biology, Biochemistry

101 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lally J, Boasman K, Brown L, Martinelli V, Cappuccio I, Sovani V, Marinaccio C, Crispino JD, Graham C, Rinaldi C. GATA-1 a potential novel biomarker for the differentiation of essential thrombocythaemia and myelofibrosis. Journal of Thrombosis and Haemostasis : Jth. PMID 30889303 DOI: 10.1111/jth.14433  0.32
2019 Zhao Z, Wang L, Volk AG, Birch NW, Stoltz KL, Bartom ET, Marshall SA, Rendleman EJ, Nestler CM, Shilati J, Schiltz GE, Crispino JD, Shilatifard A. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia. Genes & Development. 33: 61-74. PMID 30573454 DOI: 10.1101/gad.319830.118  0.36
2018 Suraneni PK, Corey SJ, Hession MJ, Ishaq R, Awomolo A, Hasan S, Shah C, Liu H, Wickrema A, Debili N, Crispino JD, Eklund EA, Chen Y. Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity. Blood Advances. 2: 3540-3552. PMID 30538113 DOI: 10.1182/bloodadvances.2018021923  0.4
2018 Fu C, Shi X, Gong Y, Wan Y, Sun Z, Shi H, Wang Z, Marinaccio C, Crispino JD, Xu K. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 50: 2314-2328. PMID 30423551 DOI: 10.1159/000495092  0.32
2018 Payton M, Cheung HK, Ninniri MSS, Marinaccio C, Wayne WC, Hanestad K, Crispino JD, Juan G, Coxon A. Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes. Molecular Cancer Therapeutics. PMID 30266802 DOI: 10.1158/1535-7163.MCT-18-0186  0.32
2018 Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutiérrez-Díaz BT, Wang KK, Johnson MR, Volk A, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas PM, Goo YA, ... ... Crispino JD, et al. USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30224337 DOI: 10.1158/1078-0432.CCR-18-1740  0.36
2018 Fu C, Wen QJ, Marinaccio C, Ling T, Chen W, Bulic M, Lasho T, Tefferi A, Crispino JD, Xu K. AKT activation is a feature of CALR mutant myeloproliferative neoplasms. Leukemia. PMID 30082822 DOI: 10.1038/s41375-018-0224-8  0.32
2018 Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism. Blood. PMID 29844011 DOI: 10.1182/blood-2017-10-811760  0.44
2018 Yang X, Lu B, Sun X, Han C, Fu C, Xu K, Wang M, Li D, Chen Z, Opal P, Wen Q, Crispino JD, Wang QF, Huang Z. ANP32A regulates histone H3 acetylation and promotes leukemogenesis. Leukemia. PMID 29467488 DOI: 10.1038/s41375-018-0010-7  0.32
2017 Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, ... ... Crispino JD, et al. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. The Journal of Clinical Investigation. PMID 28240607 DOI: 10.1172/JCI82905  0.4
2017 Hu D, Gao X, Cao K, Morgan MA, Mas G, Smith ER, Volk AG, Bartom ET, Crispino JD, Di Croce L, Shilatifard A. Not All H3K4 Methylations Are Created Equal: Mll2/COMPASS Dependency in Primordial Germ Cell Specification. Molecular Cell. 65: 460-475.e6. PMID 28157506 DOI: 10.1016/j.molcel.2017.01.013  0.36
2017 Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR, Bartom ET, Gilmore JM, Florens L, Washburn MP, Sullivan KD, Espinosa JM, Cannova J, Zhang J, Smith ER, Crispino JD, et al. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. Cell. PMID 28065413 DOI: 10.1016/j.cell.2016.12.011  0.36
2016 Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with down syndrome. Leukemia. PMID 27285583 DOI: 10.1038/leu.2016.164  0.92
2016 McNulty M, Crispino JD. iPSCs Offer a New Look at GATA1-Trisomy 21 Cooperation. Cell Stem Cell. 18: 563-4. PMID 27152438 DOI: 10.1016/j.stem.2016.04.007  0.92
2015 Jeremy Wen Q, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, ... ... Crispino JD, et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine. PMID 26569382 DOI: 10.1038/nm.3995  0.92
2015 Volk A, Crispino JD. The role of the chromatin assembly complex (CAF-1) and its p60 subunit (CHAF1b) in homeostasis and disease. Biochimica Et Biophysica Acta. 1849: 979-86. PMID 26066981 DOI: 10.1016/j.bbagrm.2015.05.009  0.92
2015 Chlon TM, McNulty M, Goldenson B, Rosinski A, Crispino JD. Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression. Haematologica. 100: 575-84. PMID 25682601 DOI: 10.3324/haematol.2014.112714  0.92
2015 Goldenson B, Kirsammer G, Stankiewicz MJ, Wen QJ, Crispino JD. Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation. Blood. 125: 2141-50. PMID 25670627 DOI: 10.1182/blood-2014-12-615401  0.92
2015 Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA. Targeting novel signaling pathways for resistant acute myeloid leukemia. Molecular Genetics and Metabolism. 114: 397-402. PMID 25533111 DOI: 10.1016/j.ymgme.2014.11.017  0.92
2015 Shaham L, Vendramini E, Ge Y, Goren Y, Birger Y, Tijssen MR, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Pitman H, Weiss MJ, Michaeli S, Sredni B, ... ... Crispino JD, et al. MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood. 125: 1292-301. PMID 25533034 DOI: 10.1182/blood-2014-06-581892  0.92
2014 Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, ... ... Crispino JD, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics. 46: 618-23. PMID 24747640 DOI: 10.1038/ng.2949  0.92
2014 Crispino JD, Weiss MJ. Erythro-megakaryocytic transcription factors associated with hereditary anemia. Blood. 123: 3080-8. PMID 24652993 DOI: 10.1182/blood-2014-01-453167  0.92
2014 Liu L, Wen Q, Gong R, Gilles L, Stankiewicz MJ, Li W, Guo M, Li L, Sun X, Li W, Crispino JD, Huang Z. PSTPIP2 dysregulation contributes to aberrant terminal differentiation in GATA-1-deficient megakaryocytes by activating LYN. Cell Death & Disease. 5: e988. PMID 24407241 DOI: 10.1038/cddis.2013.512  0.92
2014 Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia Oncogene. DOI: 10.1038/onc.2014.14  0.92
2013 Malinge S, Chlon T, Doré LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood. 122: e33-43. PMID 23980066 DOI: 10.1182/blood-2013-05-503011  0.92
2013 Krause DS, Crispino JD. Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6084-8. PMID 23963861 DOI: 10.1158/1078-0432.CCR-12-2604  0.92
2013 Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, ... ... Crispino JD, et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 27: 1882-90. PMID 23748344 DOI: 10.1038/leu.2013.167  0.92
2013 Lasho T, Johnson SH, Smith DI, Crispino JD, Pardanani A, Vasmatzis G, Tefferi A. Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. American Journal of Hematology. 88: 741-6. PMID 23733509 DOI: 10.1002/ajh.23495  0.92
2013 Birger Y, Goldberg L, Chlon TM, Goldenson B, Muler I, Schiby G, Jacob-Hirsch J, Rechavi G, Crispino JD, Izraeli S. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder. Blood. 122: 988-98. PMID 23719302 DOI: 10.1182/blood-2012-10-460998  0.92
2013 Stankiewicz MJ, Crispino JD. AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL Leukemia. 27: 1339-1347. PMID 23380710 DOI: 10.1038/leu.2013.33  0.92
2013 Malinge S, Thiollier C, Chlon TM, Doré LC, Diebold L, Bluteau O, Mabialah V, Vainchenker W, Dessen P, Winandy S, Mercher T, Crispino JD. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood. 121: 2440-51. PMID 23335373 DOI: 10.1182/blood-2012-08-450627  0.92
2012 Thiollier C, Pflumio F, Ballerini P, Crispino JD, Bernard O, Mercher T. [Novel ETO2-GLIS2 fusion and therapeutic strategy in acute megakaryoblastic leukemia]. MéDecine Sciences : M/S. 28: 1013-6. PMID 23171910 DOI: 10.1051/medsci/20122811025  0.92
2012 Crispino JD, Le Beau MM. BMP meets AML: induction of BMP signaling by a novel fusion gene promotes pediatric acute leukemia. Cancer Cell. 22: 567-8. PMID 23153530 DOI: 10.1016/j.ccr.2012.10.008  0.92
2012 Chlon TM, Crispino JD. Combinatorial regulation of tissue specification by GATA and FOG factors. Development (Cambridge, England). 139: 3905-16. PMID 23048181 DOI: 10.1242/dev.080440  0.92
2012 Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Guégan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, ... ... Crispino JD, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. The Journal of Experimental Medicine. 209: 2017-31. PMID 23045605 DOI: 10.1084/jem.20121343  0.92
2012 Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, ... ... Crispino JD, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 150: 575-89. PMID 22863010 DOI: 10.1016/j.cell.2012.06.032  0.92
2012 Crispino JD. JAKing up AML1-ETO. Blood. 120: 703-4. PMID 22835885 DOI: 10.1182/blood-2012-05-413104  0.92
2012 Chlon TM, Doré LC, Crispino JD. Cofactor-mediated restriction of GATA-1 chromatin occupancy coordinates lineage-specific gene expression. Molecular Cell. 47: 608-21. PMID 22771118 DOI: 10.1016/j.molcel.2012.05.051  0.92
2012 Keerthivasan G, Liu H, Gump JM, Dowdy SF, Wickrema A, Crispino JD. A novel role for survivin in erythroblast enucleation. Haematologica. 97: 1471-9. PMID 22491741 DOI: 10.3324/haematol.2011.061093  0.92
2012 Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, et al. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. American Journal of Hematology. 87: 562-8. PMID 22460584 DOI: 10.1002/ajh.23169  0.92
2012 Doré LC, Chlon TM, Brown CD, White KP, Crispino JD. Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. Blood. 119: 3724-33. PMID 22383799 DOI: 10.1182/blood-2011-09-380634  0.92
2012 Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. The Journal of Clinical Investigation. 122: 948-62. PMID 22354171 DOI: 10.1172/JCI60455  0.92
2012 Galat V, Malchenko S, Galat Y, Ishkin A, Nikolsky Y, Kosak ST, Soares BM, Iannaccone P, Crispino JD, Hendrix MJ. A model of early human embryonic stem cell differentiation reveals inter- and intracellular changes on transition to squamous epithelium. Stem Cells and Development. 21: 1250-63. PMID 21861759 DOI: 10.1089/scd.2010.0578  0.92
2011 Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, et al. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal. 1: e7. PMID 23471017 DOI: 10.1038/bcj.2011.4  0.92
2011 Rice KL, Lin X, Wolniak K, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P, Levine R, Golub T, Gilliland DG, Crispino JD, Licht JD, Zhang W. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer Journal. 1: e40. PMID 22829077 DOI: 10.1038/bcj.2011.39  0.92
2011 Khan I, Malinge S, Crispino JD. Myeloid leukemia in down syndrome Critical Reviews in Oncogenesis. 16: 25-36. PMID 22150305  0.92
2011 Wen Q, Goldenson B, Crispino JD. Normal and malignant megakaryopoiesis. Expert Reviews in Molecular Medicine. 13: e32. PMID 22018018 DOI: 10.1017/S1462399411002043  0.92
2011 Keerthivasan G, Wickrema A, Crispino JD. Erythroblast enucleation. Stem Cells International. 2011: 139851. PMID 22007239 DOI: 10.4061/2011/139851  0.92
2011 Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Current Opinion in Oncology. 23: 609-16. PMID 21993415 DOI: 10.1097/CCO.0b013e32834d1b22  0.92
2011 Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, Sims E, Wei L, Vemula S, Nabinger SC, Goodwin CB, Chan RJ, Traina F, Visconte V, Tiu RV, Lewis TA, ... ... Crispino JD, et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell. 20: 357-69. PMID 21907926 DOI: 10.1016/j.ccr.2011.07.016  0.92
2011 Eliades A, Papadantonakis N, Bhupatiraju A, Burridge KA, Johnston-Cox HA, Migliaccio AR, Crispino JD, Lucero HA, Trackman PC, Ravid K. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. The Journal of Biological Chemistry. 286: 27630-8. PMID 21665949 DOI: 10.1074/jbc.M111.243113  0.92
2011 Doré LC, Crispino JD. Transcription factor networks in erythroid cell and megakaryocyte development. Blood. 118: 231-9. PMID 21622645 DOI: 10.1182/blood-2011-04-285981  0.92
2010 Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD. Overexpression of survivin initiates hematologic malignancies in vivo Leukemia. 24: 1920-1926. PMID 20882051 DOI: 10.1038/leu.2010.198  0.92
2010 Huang QQ, Perlman H, Huang Z, Birkett R, Kan L, Agrawal H, Misharin A, Gurbuxani S, Crispino JD, Pope RM. FLIP: a novel regulator of macrophage differentiation and granulocyte homeostasis. Blood. 116: 4968-77. PMID 20724542 DOI: 10.1182/blood-2009-11-252841  0.92
2010 Keerthivasan G, Small S, Liu H, Wickrema A, Crispino JD. Vesicle trafficking plays a novel role in erythroblast enucleation. Blood. 116: 3331-40. PMID 20644112 DOI: 10.1182/blood-2010-03-277426  0.92
2010 Gao Z, Huang Z, Olivey HE, Gurbuxani S, Crispino JD, Svensson EC. FOG-1-mediated recruitment of NuRD is required for cell lineage re-enforcement during haematopoiesis. The Embo Journal. 29: 457-68. PMID 20010697 DOI: 10.1038/emboj.2009.368  0.92
2009 Bhat R, Malinge S, Gamis AS, Sorrell AD, Hilden JM, Ketterling RP, Paietta E, Tallman MS, Crispino JD. Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia Leukemia. 23: 2159-2160. PMID 19657363 DOI: 10.1038/leu.2009.159  0.92
2009 Huang Z, Dore LC, Li Z, Orkin SH, Feng G, Lin S, Crispino JD. GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Molecular and Cellular Biology. 29: 5168-80. PMID 19620289 DOI: 10.1128/MCB.00482-09  0.92
2009 Chou ST, Khandros E, Bailey LC, Nichols KE, Vakoc CR, Yao Y, Huang Z, Crispino JD, Hardison RC, Blobel GA, Weiss MJ. Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood. 114: 983-94. PMID 19491391 DOI: 10.1182/blood-2009-03-207944  0.92
2009 Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, ... ... Crispino JD, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 114: 144-7. PMID 19420352 DOI: 10.1182/blood-2009-03-210039  0.92
2009 Wen Q, Leung C, Huang Z, Small S, Reddi AL, Licht JD, Crispino JD. Survivin is not required for the endomitotic cell cycle of megakaryocytes. Blood. 114: 153-6. PMID 19339696 DOI: 10.1182/blood-2008-11-190801  0.92
2009 Stankiewicz MJ, Crispino JD. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood. 113: 3337-47. PMID 19168790 DOI: 10.1182/blood-2008-08-174813  0.92
2009 Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 113: 2619-28. PMID 19139078 DOI: 10.1182/blood-2008-11-163501  0.92
2008 McCrann DJ, Yezefski T, Nguyen HG, Papadantonakis N, Liu H, Wen Q, Crispino JD, Ravid K. Survivin overexpression alone does not alter megakaryocyte ploidy nor interfere with erythroid/megakaryocytic lineage development in transgenic mice. Blood. 111: 4092-5. PMID 18245663 DOI: 10.1182/blood-2007-11-122150  0.92
2008 Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 111: 767-75. PMID 17901249 DOI: 10.1182/blood-2007-04-085670  0.92
2007 Huang Z, Richmond TD, Muntean AG, Barber DL, Weiss MJ, Crispino JD. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. The Journal of Clinical Investigation. 117: 3890-9. PMID 18060035 DOI: 10.1172/JCI33010  0.92
2007 Wickrema A, Crispino JD. Erythroid and megakaryocytic transformation Oncogene. 26: 6803-6815. PMID 17934487 DOI: 10.1038/sj.onc.1210763  0.92
2007 Norton A, Fisher C, Liu H, Wen Q, Mundschau G, Fuster JL, Hasle H, Zeller B, Webb DK, O'Marcaigh A, Sorrell A, Hilden J, Gamis A, Crispino JD, Vyas P. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 110: 1077-9. PMID 17644747 DOI: 10.1182/blood-2007-03-080374  0.92
2007 Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. The Journal of Experimental Medicine. 204: 1603-11. PMID 17576776 DOI: 10.1084/jem.20062395  0.92
2007 Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, Crispino JD, Le Beau MM. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 110: 719-26. PMID 17420284 DOI: 10.1182/blood-2007-01-068809  0.92
2007 Muntean AG, Pang L, Poncz M, Dowdy SF, Blobel GA, Crispino JD. Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization. Blood. 109: 5199-207. PMID 17317855 DOI: 10.1182/blood-2006-11-059378  0.92
2007 Vyas P, Crispino JD. Molecular insights into Down syndrome-associated leukemia. Current Opinion in Pediatrics. 19: 9-14. PMID 17224656 DOI: 10.1097/MOP.0b013e328013e7b2  0.92
2007 Crispino JD. On the origins of megakaryocytes Blood. 109: 1340-1341. DOI: 10.1182/blood-2006-12-060269  0.92
2006 Muntean AG, Ge Y, Taub JW, Crispino JD. Transcription factor GATA-1 and Down syndrome leukemogenesis. Leukemia & Lymphoma. 47: 986-97. PMID 16840187 DOI: 10.1080/10428190500485810  0.92
2006 Xu Y, Leung CG, Lee DC, Kennedy BK, Crispino JD. MTB, the murine homolog of condensin II subunit CAP-G2, represses transcription and promotes erythroid cell differentiation. Leukemia. 20: 1261-9. PMID 16673016 DOI: 10.1038/sj.leu.2404252  0.92
2006 Crispino JD. Up and down in Down syndrome: AMKL Blood. 107: 1251-1252. DOI: 10.1182/blood-2005-11-4672  0.92
2005 Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for survivin in hematopoietic cell development. Proceedings of the National Academy of Sciences of the United States of America. 102: 11480-5. PMID 16055565 DOI: 10.1073/pnas.0500303102  0.92
2005 Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 106: 1223-31. PMID 15860665 DOI: 10.1182/blood-2005-02-0551  0.92
2005 Crispino JD. GATA1 in normal and malignant hematopoiesis. Seminars in Cell & Developmental Biology. 16: 137-47. PMID 15659348 DOI: 10.1016/j.semcdb.2004.11.002  0.92
2005 Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatric Blood & Cancer. 44: 40-4. PMID 15390312 DOI: 10.1002/pbc.20066  0.92
2004 Taub JW, Mundschau G, Ge Y, Poulik JM, Qureshi F, Jensen T, James SJ, Matherly LH, Wechsler J, Crispino JD. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 104: 1588-9. PMID 15317736 DOI: 10.1182/blood-2004-04-1563  0.92
2004 Smith ED, Xu Y, Tomson BN, Leung CG, Fujiwara Y, Orkin SH, Crispino JD. More than blood, a novel gene required for mammalian postimplantation development. Molecular and Cellular Biology. 24: 1168-73. PMID 14729962 DOI: 10.1128/MCB.24.3.1168-1173.2004  0.92
2004 Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 103: 399-406. PMID 14512321 DOI: 10.1182/blood-2003-05-1556  0.92
2003 Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells, Molecules & Diseases. 31: 351-6. PMID 14636651 DOI: 10.1016/j.bcmd.2003.08.001  0.92
2003 Karnauskas R, Niu Q, Talapatra S, Plas DR, Greene ME, Crispino JD, Rudin CM. Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo. Oncogene. 22: 688-98. PMID 12569361 DOI: 10.1038/sj.onc.1206159  0.92
2003 Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 101: 4298-300. PMID 12560215 DOI: 10.1182/blood-2002-12-3904  0.92
2002 Wang X, Crispino JD, Letting DL, Nakazawa M, Poncz M, Blobel GA. Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. The Embo Journal. 21: 5225-34. PMID 12356738 DOI: 10.1093/emboj/cdf527  0.92
2002 Tevosian SG, Albrecht KH, Crispino JD, Fujiwara Y, Eicher EM, Orkin SH. Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2. Development (Cambridge, England). 129: 4627-34. PMID 12223418  0.92
2002 Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics. 32: 148-52. PMID 12172547 DOI: 10.1038/ng955  0.92
2002 Chang AN, Cantor AB, Fujiwara Y, Lodish MB, Droho S, Crispino JD, Orkin SH. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proceedings of the National Academy of Sciences of the United States of America. 99: 9237-42. PMID 12077323 DOI: 10.1073/pnas.142302099  0.92
2002 Crispino JD, Orkin SH. The use of altered specificity mutants to probe specific protein-protein interactions involved in the activation of GATA-1 target genes. Methods (San Diego, Calif.). 26: 84-92. PMID 12054907 DOI: 10.1016/S1046-2023(02)00010-5  0.92
2001 Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD, Orkin SH. Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors Genes and Development. 15: 839-844. PMID 11297508 DOI: 10.1101/gad.875201  0.92
2000 Querfurth E, Schuster M, Kulessa H, Crispino JD, Döderlein G, Orkin SH, Graf T, Nerlov C. Antagonism between C/EBPβ and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors Genes and Development. 14: 2515-2525. PMID 11018018 DOI: 10.1101/gad.177200  0.92
2000 Deconinck AE, Mead PE, Tevosian SG, Crispino JD, Katz SG, Zon LI, Orkin SH. FOG acts as a repressor of red blood cell development in Xenopus Development. 127: 2031-2040. PMID 10769228  0.92
2000 Nichols KE, Crispino JD, Poncz M, White JG, Orkin SH, Maris JM, Weiss MJ. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA 1 Nature Genetics. 24: 266-270. PMID 10700180 DOI: 10.1038/73480  0.92
1999 Crispino JD, Lodish MB, MacKay JP, Orkin SH. Use of altered specificity mutants to probe a specific protein-protein interaction in differentiation: The GATA-1:FOG complex Molecular Cell. 3: 219-228. PMID 10078204 DOI: 10.1016/S1097-2765(00)80312-3  0.92
1997 Macmillan AM, Mccaw PS, Crispino JD, Sharp PA. SC35-mediated reconstitution of splicing in U2AF-depleted nuclear extract Proceedings of the National Academy of Sciences of the United States of America. 94: 133-136. PMID 8990173 DOI: 10.1073/pnas.94.1.133  0.92
1996 Crispino JD, Mermoud JE, Lamond AI, Sharp PA. Cis-acting elements distinct from the 5' splice site promote U1-independent pre-mRNA splicing. Rna (New York, N.Y.). 2: 664-73. PMID 8756409  0.92
1995 Crispino JD, Sharp PA. A U6 snRNA:pre-mRNA interaction can be rate-limiting for U1-independent splicing Genes and Development. 9: 2314-2323. PMID 7557384  0.92
1994 Crispino JD, Blencowe BJ, Sharp PA. Complementation by SR proteins of pre-mRNA splicing reactions depleted of U1 snRNP. Science (New York, N.Y.). 265: 1866-9. PMID 8091213  0.92
1991 Lessard PA, Allen RD, Bernier F, Crispino JD, Fujiwara T, Beachy RN. Multiple nuclear factors interact with upstream sequences of differentially regulated β-conglycinin genes Plant Molecular Biology. 16: 397-413. PMID 1893110 DOI: 10.1007/BF00023991  0.92
Show low-probability matches.